Related references
Note: Only part of the references are listed.Pioglitazone and Bladder Cancer A population-based study of Taiwanese
Chin-Hsiao Tseng
DIABETES CARE (2012)
Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials
Peter M. Rothwell et al.
LANCET (2012)
Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database
Krishnan Bhaskaran et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Screening for Bladder Cancer: US Preventive Services Task Force Recommendation Statement
Virginia A. Moyer
ANNALS OF INTERNAL MEDICINE (2011)
Exposure to statins and risk of common cancers: a series of nested case-control studies
Yana Vinogradova et al.
BMC CANCER (2011)
Association Between Diagnosed Diabetes and Self-Reported Cancer Among US Adults Findings from the 2009 Behavioral Risk Factor Surveillance System
Chaoyang Li et al.
DIABETES CARE (2011)
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone Interim report of a longitudinal cohort study
James D. Lewis et al.
DIABETES CARE (2011)
Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan
C-H. Tseng
DIABETOLOGIA (2011)
Validation of The Health Improvement Network (THIN) database for epidemiologic studies of chronic kidney disease
Michelle R. Denburg et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Validation and validity of diagnoses in the General Practice Research Database: a systematic review
Emily Herrett et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Validity of diagnostic coding within the General Practice Research Database: a systematic review
Nada F. Khan et al.
BRITISH JOURNAL OF GENERAL PRACTICE (2010)
Global estimates of the prevalence of diabetes for 2010 and 2030
J. E. Shaw et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
Responding to an FDA Warning - Geographic Variation in the Use of Rosiglitazone.
Nilay D. Shah et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Thiazolidinediones and Fractures in Men and Women
Colin R. Dormuth et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
Cancer incidence in The Health Improvement Network
Kevin Haynes et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
Validation of death and suicide recording on the THIN UK primary care database
Gillian C. Hall
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection
Vincent Lo Re et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
A meta-analysis on the association between bladder cancer and occupation
Raoul C. Reulen et al.
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY (2008)
Purposeful selection of variables in logistic regression
Zoran Bursac et al.
SOURCE CODE FOR BIOLOGY AND MEDICINE (2008)
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus - A meta-analysis of randomized trials
A. Michael Lincoff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Long-term risk of cardiovascular events with rosiglitazone - A meta-analysis
Sonal Singh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research
James D. Lewis et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Race, ethnicity, and use of thiazolidinediones among US adults with diabetes
Christina L. Aquilante et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Diabetes mellitus and risk of bladder cancer: a meta-analysis
S. C. Larsson et al.
DIABETOLOGIA (2006)
Attenuation of peroxisome proliferator-activated receptor γ(PPARγ) mediates gastrin-stimulated colorectal cancer cell proliferation
Albert J. Chang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
PPAR-γ ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells
Nomeli P. Nunez et al.
CANCER LETTERS (2006)
Rosiglitazone suppresses human lung carcinoma cell growth through PPAR-γ-dependent and PPARγ-independent signal pathways
SW Han et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Risk of cancer in a large cohort of nonaspirin NSAID users:: a population-based study
HT Sorensen et al.
BRITISH JOURNAL OF CANCER (2003)
Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists
R Yoshimura et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Evaluating medication effects outside of clinical trials: New-user designs
WA Ray
AMERICAN JOURNAL OF EPIDEMIOLOGY (2003)
Role of peroxisome proliferator-activated receptor γ and its ligands in non-neoplastic and neoplastic human urothelial cells
K Nakashiro et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer
E Mueller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
